Additionally, TP53 GOF mutations were associated with a relatively lower histologic grade than non-GOF mutations.<h4>Conclusions</h4>TP53 GOF mutations were associated with poorer ROS1-TKI treatment outcomes but improved immunotherapy response in NSCLC, with elevated immune activities and distinct molecular profiles. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.